The market for immune biologics has grown increasingly crowded in recent years with the launches of newer brands such as Simponi, Cimzia, and Stelara looking to take share away from longer-marketed products such as the TNF-alpha inhibitors Enbrel and Humira, as well as Remicade. Despite some of the advantages of newer therapies, commercial and Medicare plans continue to favor longer-marketed products that have known efficacy and safety/tolerability track records. Tiering data from Fingertip Formulary show that health plans have increased their advantaged tier coverage (Tier 1 or 2 placement) for some of these newer therapies in the past year, but plans continue to offer the best tier positions to the longer-marketed brands. Importantly, surveyed health plans report that increased spending on prescription drugs for rheumatoid arthritis, Crohn's disease, and psoriasis over the past five years have not resulted in flat or lower costs for non-drug (i.e., medical) expenses. This finding suggests that plans are not seeing the desired results for greater prescription drug costs and may make them more interested in TNF-alpha inhibitors and drugs that feature an alternative mechanism of action (MOA) that can reduce medical costs. 26% of surveyed plans report that they favor a single TNF-alpha inhibitor brand for treating RA, and they are split between Enbrel and Humira. A survey of pharmacy directors resulted in similar findings for therapies with an alternative MOA.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details